Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities
Authors
Keywords
-
Journal
HEPATOLOGY
Volume 53, Issue 2, Pages 695-704
Publisher
Wiley
Online
2011-01-12
DOI
10.1002/hep.24145
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines
- (2010) Ling Xu et al. BMC CANCER
- KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer
- (2010) Antonio Jimeno et al. CANCER JOURNAL
- Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver
- (2010) S. Benhamouche et al. GENES & DEVELOPMENT
- Genetics of Biliary Tract Cancers and Emerging Targeted Therapies
- (2010) Aram F. Hezel et al. JOURNAL OF CLINICAL ONCOLOGY
- Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
- (2010) Sam J. Lubner et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
- (2010) Birgit Gruenberger et al. LANCET ONCOLOGY
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preliminary Experience of Cetuximab in the Treatment of Advanced-Stage Biliary Tract Cancer
- (2010) Ping-Ying Chang et al. ONKOLOGIE
- Treatment of biliary tract cancer with NVP-AEW541: Mechanisms of action and resistance
- (2010) Samuel Wolf WORLD JOURNAL OF GASTROENTEROLOGY
- Hepatic Stellate Cells May Relate to Progression of Intrahepatic Cholangiocarcinoma
- (2009) Hirohisa Okabe et al. ANNALS OF SURGICAL ONCOLOGY
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
- (2009) C Bengala et al. BRITISH JOURNAL OF CANCER
- A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
- (2009) Ramesh K. Ramanathan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Intrahepatic Cholangiocarcinoma Progression: Prognostic Factors and Basic Mechanisms
- (2009) Alphonse E. Sirica et al. Clinical Gastroenterology and Hepatology
- Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder
- (2009) Nafis Shafizadeh et al. HUMAN PATHOLOGY
- Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
- (2009) Andrew X Zhu et al. LANCET ONCOLOGY
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- TGFβ in Cancer
- (2008) Joan Massagué CELL
- RarePIK3CA hotspot mutations in carcinomas of the biliary tract
- (2008) Marc-Oliver Riener et al. GENES CHROMOSOMES & CANCER
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic Therapy for Biliary Tract Cancers
- (2008) A. F. Hezel et al. ONCOLOGIST
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started